Organogenesis (NASDAQ:ORGO) Shares Gap Up – Still a Buy?

Organogenesis (NASDAQ:ORGO)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $4.83, but opened at $5.24. Organogenesis shares last traded at $5.0650, with a volume of 807,230 shares.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Weiss Ratings restated a “sell (d+)” rating on shares of Organogenesis in a research note on Monday. BTIG Research reiterated a “buy” rating and set a $9.00 target price on shares of Organogenesis in a report on Monday. Finally, Wall Street Zen raised Organogenesis from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Organogenesis has a consensus rating of “Hold” and an average target price of $8.00.

Organogenesis Trading Up 1.9%

The company has a market cap of $668.82 million, a P/E ratio of -43.92 and a beta of 1.47. The business’s 50-day moving average price is $4.81 and its 200 day moving average price is $4.48. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.88 and a current ratio of 3.32.

Organogenesis (NASDAQ:ORGO) last issued its earnings results on Thursday, November 6th. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.11. Organogenesis had a negative net margin of 1.30% and a positive return on equity of 4.01%. The company had revenue of $150.86 million for the quarter, compared to analysts’ expectations of $134.10 million. As a group, analysts expect that Organogenesis will post -0.07 earnings per share for the current year.

Insider Transactions at Organogenesis

In other news, Director Glenn H. Nussdorf sold 187,957 shares of the firm’s stock in a transaction that occurred on Wednesday, November 26th. The stock was sold at an average price of $5.29, for a total value of $994,292.53. Following the completion of the sale, the director directly owned 2,765,591 shares of the company’s stock, valued at $14,629,976.39. This trade represents a 6.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders sold a total of 300,000 shares of company stock valued at $1,592,120 in the last 90 days. 33.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ORGO. Quarry LP bought a new position in Organogenesis during the third quarter worth $25,000. State of Alaska Department of Revenue bought a new stake in shares of Organogenesis during the 3rd quarter worth about $25,000. Farther Finance Advisors LLC acquired a new position in Organogenesis in the 2nd quarter valued at about $35,000. Ground Swell Capital LLC acquired a new position in Organogenesis in the 2nd quarter valued at about $39,000. Finally, Regent Peak Wealth Advisors LLC bought a new position in Organogenesis in the 3rd quarter valued at about $51,000. 49.57% of the stock is owned by institutional investors and hedge funds.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.